USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
GROWTH OPPORTUNITIES IN TARGETED CANCER THERAPY & CANCER DIAGNOSTICS, VIRAL VECTORS, MULTIPLE DISEASES, RETINAL DISEASES, AND COSMECEUTICALS
GROWTH OPPORTUNITIES IN TARGETED CANCER THERAPY & CANCER DIAGNOSTICS, VIRAL VECTORS, MULTIPLE DISEASES, RETINAL DISEASES, AND COSMECEUTICALS
19-Feb-2021
Global
Description
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) discusses developments in cancer diagnostics and targeted cancer therapy, therapeutics for MDR bacteria, viral vectors, and antibody therapeutics for multiple diseases. Further, innovations in emerging technologies such as synthetic blood and 3D printed implants have also been covered. Use of artificial intelligence/machine learning in drug discovery, viral vector design, and immune profiling are also discussed. Few innovations cover developments in cosmeceuticals for skin and hair care and protein-based sweeteners.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: Gene therapy, Age-related macular degeneration, multi-drug resistance, retinal diseases, viral vector, Lentivirus, vector purification, Pemphigus vulgaris, cosmeceuticals, miRNA , Osteogenesis imperfecta, monoclonal antibodies, antibody cocktail, COVID-19, cell simulation, AI/ML, immune profiling, cell simulation, oncolytic virus, cancer diagnostic, hypoglycemia, familial hypercholesterolemia, 3D bioprinting, synthetic blood, antimicrobial peptides, drug repurposing
Table of Contents
INNOVATIONS IN LIFE SCIENCES, HEALTH & WELLNESS
- ADAPTIVE PHAGE THERAPEUTICS, MD, US
- MERCK, NJ, US
- AURINIA PHARMACEUTICALS, CANADA
- XERIS PHARMACEUTICALS, IL, US
- BIOTHERYX, US
- TARGOVAX, NORWAY
- NYU GROSSMAN SCHOOL OF MEDICINE AND PERLMUTTER CANCER CENTER, USA
- REGENERON PHARMACEUTICALS, US
- LEIBNIZ UNIVERSITY, GERMANY
- OMNIX MEDICAL, ISRAEL
- SOM BIOTECH, SPAIN
- INTE RNA, NETHERLANDS
- MEMBIO, US
- PEKING UNIVERSITY, CHINA
- UNIVERSITY OF FLORIDA, US
- ADDITIVE ORTHOPAEDICS LLC., US
- MEREO BIOPHARMA GROUP PLC, UK
- CABALETTA BIO INC., PA,US
- NGM BIOPHARMACEUTICALS INC., CA, US
- REDHILL BIOPHARMA LTD., ISRAEL
- ELI LILLY AND COMPANY, IN, US
- OCUGEN, PA, US
- TURBINE AI, HUNGARY
- IMMUNAI, US
- TRI-K INDUSTRIES INC., US
- AMAI PROTEINS, ISRAEL
KEY CONTACTS
- KEY CONTACTS
- KEY CONTACTS
- KEY CONTACTS
- KEY CONTACTS
- KEY CONTACTS
- KEY CONTACTS
- KEY CONTACTS
Related Research
Popular Topics
| No Index | No |
|---|---|
| Podcast | No |
| Industries | Healthcare |
| WIP Number | D759-00-1D-00-00 |
| Is Prebook | No |
| Ti Codes | D759 |